The Australian Immunisation Handbook 10th Edition 2013

Pneumococcal conjugate vaccines
• Synflorix – GlaxoSmithKline (10-valent pneumococcal conjugate
vaccine; 10vPCV). Each 0.5 mL monodose vial or pre-filled syringe
contains 1 µg of pneumococcal capsular polysaccharide of serotypes
1, 5, 6B, 7F, 9V, 14, 23F and 3 µg of serotype 4, conjugated to a total of
9–16 µg of non-typeable H. influenzae protein D, 3 µg of serotype 18C
conjugated to 5–10 µg of tetanus toxoid carrier protein, and 3 µg of
serotype 19F conjugated to 3–6 µg of diphtheria toxoid carrier protein,
adsorbed onto 0.5 mg aluminium as aluminium phosphate.
• Prevenar 13 – Pfizer Australia Pty Ltd (13-valent pneumococcal
conjugate vaccine; 13vPCV). Each 0.5 mL monodose pre-filled syringe
contains 2.2 µg each of pneumococcal capsular polysaccharide of
serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F and 4.4 µg of
serotype 6B, conjugated to non-toxic Corynebacterium diphtheriae
CRM 197 protein, adsorbed onto 0.565 mg aluminium phosphate;
succinic acid; polysorbate 80.
7-valent pneumococcal conjugate vaccine (7vPCV)
A 7vPCV with the mutant non-toxic diphtheria CRM protein as the conjugating
197
protein (Prevenar) became available in Australia in 2001. Efficacy data on the
7vPCV from a pivotal trial in the United States found greater than 95% protective
efficacy against IPD caused by the serotypes contained in the vaccine. 22 A
Cochrane review of clinical trials estimated an efficacy of 80% against vaccinetype
IPD for PCVs (most, but not all, of which used CRM as the conjugating
197
protein) in children